Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan) (RAINBOW)

Viatris

Status: Completed

Conditions: Neuralgia

Treatments: Drug: Pregabalin (Lyrica) capsule

Study type: Observational

Funder types: Industry

Identifiers

NCT01256593

A0081261

Details and patient eligibility

About

The objective of this Investigation is to evaluate the safety and efficacy of Lyrica in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Lyrica will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.

Full description

All the patients whom an investigator prescribes the first Lyrica® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Enrollment: 3,827 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients need to be administered Lyrica® in order to be enrolled in the surveillance.

Exclusion criteria

• Patients not administered Lyrica®.

Trial design

3,827 participants in 1 patient group

Pregabalin (Lyrica) capsule

Description:

Patients administered "Pregabalin capsule".

Treatment:

Drug: Pregabalin (Lyrica) capsule